Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About the Ochsner Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
  • Other Publications
    • Ochsner Journal Blog

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Ochsner Journal
  • Other Publications
    • Ochsner Journal Blog
  • My alerts
  • Log in
Ochsner Journal

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About the Ochsner Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
Case ReportCASE REPORTS AND CLINICAL OBSERVATIONS
Open Access

RAD-140 Drug-Induced Liver Injury

Kenneth Leung, Priyanka Yaramada, Preeya Goyal, Cindy X. Cai, Irene Thung and Muhammad B. Hammami
Ochsner Journal December 2022, 22 (4) 361-365; DOI: https://doi.org/10.31486/toj.22.0005
Kenneth Leung
1Department of Gastroenterology and Hepatology, VA Loma Linda Healthcare System, Loma Linda, CA
2University of California, Riverside, Riverside, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priyanka Yaramada
1Department of Gastroenterology and Hepatology, VA Loma Linda Healthcare System, Loma Linda, CA
2University of California, Riverside, Riverside, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Preeya Goyal
1Department of Gastroenterology and Hepatology, VA Loma Linda Healthcare System, Loma Linda, CA
3Loma Linda University, Loma Linda, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cindy X. Cai
1Department of Gastroenterology and Hepatology, VA Loma Linda Healthcare System, Loma Linda, CA
2University of California, Riverside, Riverside, CA
3Loma Linda University, Loma Linda, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Thung
1Department of Gastroenterology and Hepatology, VA Loma Linda Healthcare System, Loma Linda, CA
3Loma Linda University, Loma Linda, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muhammad B. Hammami
1Department of Gastroenterology and Hepatology, VA Loma Linda Healthcare System, Loma Linda, CA
2University of California, Riverside, Riverside, CA
3Loma Linda University, Loma Linda, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bader.hammami@medsch.ucr.edu
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

Background: RAD-140, one of the novel selective androgen receptor modulators (SARMs), has potent anabolic effects on bones and muscles with little androgenic effect. Despite the lack of approval for its clinical use, RAD-140 is readily accessible on the consumer market. Hepatotoxicity associated with the use of SARMs has only rarely been reported in the literature.

Case Report: A 24-year-old male presented with a 2-week history of diffuse abdominal pain, scleral icterus, pruritus, and jaundice. Prior to presentation, he had been taking the health supplement RAD-140 for muscle growth for 5 weeks. He had a cholestatic pattern of liver injury, with a peak total bilirubin of 38.5 mg/dL. Liver biopsy was supportive of a diagnosis of RAD-140–associated liver injury characterized pathologically by intracytoplasmic and canalicular cholestasis with minimal portal inflammation. Symptoms and liver injury resolved after cessation of the offending agent.

Conclusion: To date, only select descriptions of the potential hepatoxicity associated with the use of SARMs, including RAD-140, have been published. Given their potential hepatoxicity and ready availability on the consumer market, RAD-140 and other SARMs should be used judiciously and under close clinical supervision until further hepatic safety data become available.

Keywords:
  • Chemical and drug induced liver injury
  • Enobosarm
  • LGD-4033
  • RAD140

INTRODUCTION

Nonsteroidal selective androgen receptor modulators (SARMs), including RAD-140, Enobosarm, and Ligandrol, promote anabolic effects on bones and muscles through binding to androgen receptors, similar to traditional anabolic-androgenic steroids such as testosterone.1-3 Unlike anabolic-androgenic steroids, SARMs do not have the unwanted androgenic effects because they are not metabolized to dihydrotestosterone by 5-alpha reductase or to estrogen by aromatase.2 Because of the high tissue selectivity of their anabolic actions, SARMs are being studied in several clinical applications, including sarcopenia, cancer-related cachexia, prostate cancer, breast cancer, and osteoporosis.1 Despite receiving a warning from the US Food and Drug Administration and being banned by the World Anti-Doping Agency, SARMs remain readily accessible in the online marketplace and are used as alternatives to anabolic-androgenic steroids for muscle and strength development.4-6 Unlike anabolic-androgenic steroids, which have a well-known hepatotoxic profile, only limited hepatic safety data are available for SARMs.3,7-12 We report a case of drug-induced liver injury caused by the use of the SARM RAD-140.

CASE REPORT

A previously healthy 24-year-old male presented to the emergency department (ED) with a 2-week history of diffuse abdominal pain, pruritus, scleral icterus, and jaundice. Approximately 2 months earlier, he had started taking up to 15 mg daily of RAD-140 for a total of 5 weeks for muscle growth. The only other medication that he took was acetaminophen 250 mg/aspirin 250 mg/caffeine 65 mg (used 4 times daily as needed for headache, no more than twice a week). He had stopped both medications 2 weeks prior to presentation as instructed by his primary care provider (PCP) because of the incidental finding of elevated liver chemistries (Table 1, Routine PCP office visit, +5 weeks).

View this table:
  • View inline
  • View popup
Table 1.

Liver Test Results

In the ED, the patient denied consuming alcohol or using any other supplements, over-the-counter or prescription medications, or recreational drugs. Physical examination was normal except for jaundice and scleral icterus. Laboratory data revealed total bilirubin of 10.8 mg/dL (reference range, 0.2-1.2 mg/dL), alkaline phosphatase of 151 IU/L (reference range, 32-91 IU/L), alanine aminotransferase of 171 IU/L (reference range, 17-63 IU/L), and aspartate aminotransferase of 71 IU/L (reference range, 15-41 IU/L). Gamma-glutamyl transpeptidase, international normalized ratio (INR), total protein, albumin, and complete blood count were within normal limits (Table 1, Emergency department encounter, +7 weeks). Hospital admission for further testing was recommended; however, the patient declined and left against medical advice.

A week after his index hospital encounter, the patient was seen in the hepatology clinic for follow-up, where he was noted to have worsening jaundice and pruritus. Blood work revealed total bilirubin of 32.3 mg/dL, alkaline phosphatase of 181 IU/L, alanine aminotransferase of 125 IU/L, aspartate aminotransferase of 82 IU/L, and INR of 0.96 (Table 1, Hepatology office visit, +8 weeks). Based on the patient's initial assessment, drug-induced liver injury from recent RAD-140 use was suspected. However, as he did not show any signs or symptoms concerning for acute liver failure that would warrant immediate hospitalization, further workup for his abnormal liver tests and short-interval follow-up were arranged. Two weeks later, he returned to the hepatology clinic, and blood work revealed total bilirubin of 24.8 mg/dL, alkaline phosphatase of 251 IU/L, alanine aminotransferase of 212 IU/L, aspartate aminotransferase of 120 IU/L, and INR of 1.47 (Table 1, Hepatology office visit, +10 weeks).

Given his significantly elevated liver tests and now elevated INR, he was urged to go to the ED, where he was admitted for closer monitoring and diagnostic evaluation. He did not display any signs or symptoms of encephalopathy. He denied any interval use of prescription or over-the-counter medications, supplements, alcohol, or recreational drugs. Serologic markers for viral hepatitis and autoimmune liver conditions were negative. Serum ferritin was significantly elevated at 1,523 ng/mL (reference range, 22-322 ng/mL), but transferrin saturation was only 21% (reference, ≤45%) and he was negative for C282Y/H63D mutations. Ceruloplasmin level was normal. Alpha-1 antitrypsin (AAT) level was normal, and AAT phenotype was Pi*MZ. Urine toxicology screen, alcohol screen, and acetaminophen level were negative. Doppler ultrasound of the liver was unremarkable. Abdominal axial computed tomography and magnetic retrograde cholangiogram revealed hepatomegaly and limited focal fatty infiltration with patent biliary tree and vasculature (Figure, A and B). Percutaneous liver biopsy revealed bile accumulation inside the hepatocytes and canaliculi (Figure, C) with minimal portal infiltrates of lymphocytes (Figure, D) and no significant steatosis, necrosis, fibrosis, stainable iron, or intracytoplasmic inclusions on periodic acid–Schiff stain, consistent with drug-induced cholestasis.

Figure.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

(A) Axial contrast-enhanced computed tomography image shows hepatomegaly and focal fatty infiltration (arrow). (B) Magnetic resonance cholangiopancreatography demonstrates patent biliary tree. (C) Liver histology illustrates hepatocellular and canalicular cholestasis (arrows) (hematoxylin and eosin [H&E] stain, magnification ×40). (D) Liver histology reveals minimal portal inflammation (arrow) (H&E stain, magnification ×20).

The patient had an unremarkable hospital course. Serial laboratory testing showed gradually improving liver chemistries and stable INR. As acute liver failure was not a concern, N-acetylcysteine was not given.

The patient was discharged on hospital day 4. He returned to the hepatology clinic for regular visits up to 5 months postdischarge. At his most recent clinic visit, his symptoms had entirely resolved, and his liver tests had markedly improved (Table 1, Postdischarge hepatology office visit, +18 weeks). The patient did not return for his next scheduled hepatology clinic visit and did not return calls to reschedule. Approximately 14 months postdischarge, he was seen at the PCP clinic for reasons unrelated to his liver injury. Routine blood work including liver tests was ordered but not completed.

DISCUSSION

This case of RAD-140–associated cholestatic liver injury had an assessed Drug-Induced Liver Injury Network causality score of 1 (probable) and a severity score of 3 (severe injury).8 To our knowledge, ours is the sixth case of SARM-associated drug-induced liver injury and the third case associated with RAD-140 use (Table 2).9-12 Similar to the previously reported cases, jaundice was the presenting symptom in our patient. Except for one case, SARM-related liver injury was either of mixed or cholestatic pattern.9-12 In our case, we observed a primarily cholestatic pattern of injury, with an initial moderate elevation in transaminases, followed by profound hyperbilirubinemia. We observed a latency period of approximately 6 weeks from cessation of the SARM to peak bilirubin levels, compared to Flores et al who reported a latency period of 5 weeks.9 Similar to Flores et al and Bedi et al, we observed a mild elevation in INR without fulminant liver failure.9,12 Liver biopsies typically demonstrate intracytoplasmic or canalicular cholestasis with minimal or nonexistent necrosis or inflammation. In all cases of SARM-related hepatoxicity to date, including ours, liver injury resolved with cessation of the offending agent. No patients developed fulminant liver failure, and no deaths occurred. While our patient did not receive any specific treatment for his liver injury, ursodeoxycholic acid may be beneficial in relieving cholestasis related to drug-induced liver injury, although data are largely lacking.13

View this table:
  • View inline
  • View popup
Table 2.

Summary of Cases of Selective Androgen Receptor Modulator (SARM)-Associated Hepatotoxicity

Our patient had a history of using acetaminophen and salicylic acid prior to the onset of his liver injury. However, acetaminophen and/or salicylic acid–related hepatoxicity was deemed unlikely because of the small accumulated dosage, and more importantly, the lack of classic zone 3 necrosis/apoptosis and/or microvesicular steatosis. On the other hand, bland cholestasis, a pathologic feature commonly observed in anabolic-androgenic steroid–induced hepatotoxicity, highly suggests cholestatic injury from RAD-140.14

The molecular mechanisms underlying SARM-induced hepatotoxicity are largely speculative. The bland cholestasis seen in both anabolic-androgenic steroid– and RAD-140/Enobosarm–associated hepatotoxicity highly suggests involvement of androgen receptors in dysregulation of bile transport. In animal studies, the bile salt export pump (BSEP), an ATP-binding cassette subfamily B member 11 (ABCB11) transporter, was reported to be involved in anabolic-androgenic steroid–induced cholestatic injury.7,15,16 Whether the association of RAD-140 with androgen receptors regulates BSEP through receptor-associated signaling pathways remains to be defined. In humans, the ABCB11 mutation was reported to increase the genetic susceptibility of anabolic-androgenic steroid–induced cholestasis.17 Although we do not know if our patient has the ABCB11 mutation, he is heterozygous for alpha-1-antitrypsin Z (Pi*MZ), a phenotype reported to be a predisposing factor for liver disease and fibrosis.18 Whether Z heterozygosity contributes to drug-induced cholestasis remains to be determined.

CONCLUSION

The accumulating cases of drug-induced liver injury from SARMs raise concern about their hepatic safety and question the tissue selectivity of these agents. We caution the use of SARMs outside of clinical investigation and advocate for tighter regulation, close monitoring, and prompt reporting of adverse events associated with SARMs.

This article meets the Accreditation Council for Graduate Medical Education and the American Board of Medical Specialties Maintenance of Certification competencies for Patient Care and Medical Knowledge.

ACKNOWLEDGMENTS

This case was presented at the American College of Gastroenterology Scientific Meeting 2020 that took place virtually October 23-28, 2020. The authors have no financial or proprietary interest in the subject matter of this article.

  • ©2022 by the author(s); Creative Commons Attribution License (CC BY)

©2022 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

REFERENCES

  1. 1.↵
    1. Solomon ZJ,
    2. Mirabal JR,
    3. Mazur DJ,
    4. Kohn TP,
    5. Lipshultz LI,
    6. Pastuszak AW
    . Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019;7(1):84-94. doi: 10.1016/j.sxmr.2018.09.006
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Christiansen AR,
    2. Lipshultz LI,
    3. Hotaling JM,
    4. Pastuszak AW
    . Selective androgen receptor modulators: the future of androgen therapy? Transl Androl Urol. 2020;9(Suppl 2):S135-S148. doi: 10.21037/tau.2019.11.02
    OpenUrlCrossRef
  3. 3.↵
    1. Basaria S,
    2. Collins L,
    3. Dillon EL,
    4. et al.
    The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87-95. doi: 10.1093/gerona/gls078
    OpenUrlCrossRefPubMed
  4. 4.↵
    FDA in brief: FDA warns against using SARMs in body building products. U.S. Food and Drug Administration. Published October 31, 2017. Accessed March 8, 2022. fda.gov/news-events/fda-brief/fda-brief-fda-warns-against-using-sarms-body-building-products
  5. 5.
    The prohibited list. World Anti-Doping Agency. Published January 1, 2022. Accessed March 8, 2022. wada-ama.org/en/prohibited-list
  6. 6.↵
    1. Van Wagoner RM,
    2. Eichner A,
    3. Bhasin S,
    4. Deuster PA,
    5. Eichner D
    . Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet [published correction appears in JAMA. 2018 Feb 20;319(7):724]. JAMA. 2017;318(20):2004-2010. doi: 10.1001/jama.2017.17069
    OpenUrlCrossRef
  7. 7.↵
    1. Solimini R,
    2. Rotolo MC,
    3. Mastrobattista L,
    4. et al.
    Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):7-16.
    OpenUrl
  8. 8.↵
    1. Regev A,
    2. Seeff LB,
    3. Merz M,
    4. et al.
    Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf. 2014;37 Suppl 1(Suppl 1):S47-S56. doi: 10.1007/s40264-014-0185-4
    OpenUrlCrossRef
  9. 9.↵
    1. Flores JE,
    2. Chitturi S,
    3. Walker S
    . Drug-induced liver injury by selective androgenic receptor modulators. Hepatol Commun. 2020;4(3):450-452. doi: 10.1002/hep4.1456
    OpenUrlCrossRef
  10. 10.
    1. Barbara M,
    2. Dhingra S,
    3. Mindikoglu AL
    . Ligandrol (LGD-4033)-induced liver injury. ACG Case Rep J. 2020;7(6):e00370. doi: 10.14309/crj.0000000000000370
    OpenUrlCrossRef
  11. 11.
    1. Barbara M,
    2. Dhingra S,
    3. Mindikoglu AL
    . Drug-induced liver injury associated with Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033). ACG Case Rep J. 2020;7(6):e00409. doi: 10.14309/crj.0000000000000409
    OpenUrlCrossRef
  12. 12.↵
    1. Bedi H,
    2. Hammond C,
    3. Sanders D,
    4. Yang HM,
    5. Yoshida EM
    . Drug-induced liver injury from enobosarm (ostarine), a selective androgen receptor modulator. ACG Case Rep J. 2021;8(1):e00518. doi: 10.14309/crj.0000000000000518
    OpenUrlCrossRef
  13. 13.↵
    1. Robles-Díaz M,
    2. Nezic L,
    3. Vujic-Aleksic V,
    4. Björnsson ES
    . Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review. Front Pharmacol. 2021;12:744488. doi: 10.3389/fphar.2021.744488
    OpenUrlCrossRef
  14. 14.↵
    1. Bond P,
    2. Llewellyn W,
    3. Van Mol P
    . Anabolic androgenic steroid-induced hepatotoxicity. Med Hypotheses. 2016;93:150-153. doi: 10.1016/j.mehy.2016.06.004
    OpenUrlCrossRef
  15. 15.↵
    1. Kullak-Ublick GA,
    2. Stieger B,
    3. Hagenbuch B,
    4. Meier PJ
    . Hepatic transport of bile salts. Semin Liver Dis. 2000;20(3):273-292. doi: 10.1055/s-2000-9426
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Pauli-Magnus C,
    2. Meier PJ
    . Hepatobiliary transporters and drug-induced cholestasis. Hepatology. 2006;44(4):778-787. doi: 10.1002/hep.21359
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. El Sherrif Y,
    2. Potts JR,
    3. Howard MR,
    4. et al.
    Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? Liver Int. 2013;33(8):1266-1270. doi: 10.1111/liv.12216
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hakim A,
    2. Moll M,
    3. Qiao D,
    4. et al.
    Heterozygosity of the alpha 1-antitrypsin Pi*Z allele and risk of liver disease. Hepatol Commun. 2021;5(8):1348-1361. doi: 10.1002/hep4.1718
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Ochsner Journal: 22 (4)
Ochsner Journal
Vol. 22, Issue 4
Dec 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Ochsner Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
RAD-140 Drug-Induced Liver Injury
(Your Name) has sent you a message from Ochsner Journal
(Your Name) thought you would like to see the Ochsner Journal web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
RAD-140 Drug-Induced Liver Injury
Kenneth Leung, Priyanka Yaramada, Preeya Goyal, Cindy X. Cai, Irene Thung, Muhammad B. Hammami
Ochsner Journal Dec 2022, 22 (4) 361-365; DOI: 10.31486/toj.22.0005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
RAD-140 Drug-Induced Liver Injury
Kenneth Leung, Priyanka Yaramada, Preeya Goyal, Cindy X. Cai, Irene Thung, Muhammad B. Hammami
Ochsner Journal Dec 2022, 22 (4) 361-365; DOI: 10.31486/toj.22.0005
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • CASE REPORT
    • DISCUSSION
    • CONCLUSION
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Differential to Terminal Ileitis: Terminal Ileum Neuroendocrine Tumor Identified on Screening Colonoscopy
  • Pelvic Synovial Sarcoma Clinically Masquerading as an Ovarian Malignancy
  • Two-Stage Pediatric Ear Reconstruction Using Preserved Native Cartilage After a Dog Bite
Show more CASE REPORTS AND CLINICAL OBSERVATIONS

Similar Articles

Keywords

  • Chemical and drug induced liver injury
  • Enobosarm
  • LGD-4033
  • RAD140

Current Post at the Blog

No Author Credit for ChatGPT

Our Content

  • Home
  • Current Issue
  • Ahead of Print
  • Archive
  • Featured Contributors
  • Ochsner Journal Blog
  • Archive at PubMed Central

Information & Forms

  • Instructions for Authors
  • Instructions for Reviewers
  • Submission Checklist
  • FAQ
  • License for Publishing-Author Attestation
  • Patient Consent Form
  • Submit a Manuscript

Services & Contacts

  • Permissions
  • Sign up for our electronic table of contents
  • Feedback Form
  • Contact Us

About Us

  • Editorial Board
  • About the Ochsner Journal
  • Ochsner Health
  • University of Queensland-Ochsner Clinical School
  • Alliance of Independent Academic Medical Centers

© 2023 Ochsner Clinic Foundation

Powered by HighWire